Body mass index, lipid metabolism and estrogens: Their impact on coronary heart disease

Current Medicinal Chemistry

Volumn 21, Issue 30, 2014, Pages 3455-3465

  Kolovou, G D ^a   Kolovou, V ^a   Kostakou, P M ^b   Mavrogeni, S ^a  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

^b THRIASIO GENERAL HOSPITAL   (Greece)

Author keywords

Body fat; Coronary heart disease; Estrogens; Hormone replacement therapy; Lipids; Menopause

Indexed keywords

ESTROGEN; LIPID; LIPOPROTEIN; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE;

ADIPOSE TISSUE; ARTICLE; BODY COMPOSITION; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; HUMAN; ISCHEMIC HEART DISEASE; LIPID METABOLISM; LIPOPROTEIN METABOLISM; MENOPAUSE; METABOLIC SYNDROME X; WEIGHT REDUCTION; CORONARY DISEASE; FEMALE; HORMONE SUBSTITUTION; METABOLISM; PATHOLOGY; POSTMENOPAUSE;

ADIPOSE TISSUE; BODY MASS INDEX; CORONARY DISEASE; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; LIPID METABOLISM; POSTMENOPAUSE; PROGESTINS;

EID: 84926350520     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666140901114515     Document Type: Article

References (145)

1. Bessesen, D.H.; Faggioni, R. Recently identified peptides involved in the regulation of body weight. Semin. Oncol., 1998, 25, 28-32.
2. Toth, M.J.; Tchernof, A.; Sites, C.K.; Poehlman, E.T. Effect of menopausal status on body composition and abdominal fat distribution. Int. J. Obes. Relat. Metab. Disord., 2000, 24, 226-231.
3. Canoy, D. Coronary heart disease and body fat distribution. Curr. Atheroscler. Rep., 2010, 12, 125-133.
4. Spady, D.K.; Turley, S.D.; Dietschy, J.M. Dissociation of hepatic cholesterol synthesis from hepatic low-density lipoprotein uptake and biliary cholesterol saturation in female and male hamsters of different ages. Biochim. Biophys. Acta., 1983, 753(3), 381-392.
5. Karita, K.; Yamanouchi, Y.; Takano, T.; Oku, J.; Kisaki, T.; Yano, E. Associations of blood selenium and serum lipid levels in Japanese premenopausal and postmenopausal women. Menopause, 2008, 15(1), 119-124.
6. Lu, H.; Higashikata, T.; Inazu, A.; Nohara, A.; Yu, W.; Shimizu, M.; Mabuchi, H. Association of estrogen receptor-alpha gene polymorphisms with coronary artery disease in patients with familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol., 2002, 22(5), 817-823.
7. Kolovou, G.D.; Anagnostopoulou, K.K.; Daskalopoulou, S.S.; Mikhailidis, D.P.; Cokkinos, D.V. Clinical relevance of postprandial lipaemia. Curr. Med. Chem., 2005, 12(17), 1931-1945.
8. Nordestgaard, B.G.; Freiberg, J.J. Clinical Relevance of Nonfasting and Postprandial Hypertriglyceridemia and Remnant Cholesterol. Curr. Vasc. Pharmacol., 2011, 9(3), 281-286.
9. Kolovou, G.D.; Mikhailidis, D.P.; Nordestgaard, B.G.; Bilianou, H.; Panotopoulos, G. Definition of Postprandial Lipaemia. Curr. Vasc. Pharmacol., 2011, 9(3), 292-301.
10. Kolovou, G.D.; Anagnostopoulou, K.K.; Pavlidis, A.N.; Salpea, K.D.; Hoursalas, I.S.; Manolis, A.; Cokkinos, D.V. Postprandial lipaemia in menopausal women with metabolic syndrome. Maturitas, 2006, 55(1), 19-26.
11. Kolovou, G.D.; Anagnostopoulou, K.K.; Salpea, K.D.; Pilatis, N.D.; Iraklianou, S.; Grapsa, G.; Pantelakis, A.; Tsarpalis, K.; Kapnia, E.; Cokkinos, D.V. Postprandial lipemia in postmenopausal women with high fasting high-density lipoprotein cholesterol. Am. J. Med. Sci., 2006, 331(1), 10-16.
12. Wade, G.N. Some effects of ovarian hormones on food intake and body weight in female rats. J. Comp. Physiol. Psychol., 1975, 88(1), 183-193.
13. Lawrence, C.B.; Snape, A.C.; Baudoin, F.M.; Luckman, S.M. Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centers. Endocrinology, 2002, 143(1), 155-162.
14. Kirchgessner, A.L.; Sclafani, A. PVN-hindbrain pathway involved in the hypothalamic hyperphagia-obesity syndrome. Physiol. Behav., 1988, 42(6), 517-528.
15. Maeda. K.; Nagatani, S.; Estacio, M.A.; Tsukamura, H. Novel estrogen feedback sites associated with stress-induced suppression of luteinizing hormone secretion in female rats. Cell. Mol. Neurobiol., 1996, 16(3), 311-324.
16. Poehlman, E.T.; Toth, M.J.; Gardner, A.W. Changes in energy balance and body composition at menopause: a controlled longitudinal study. Ann. Intern. Med., 1995, 123(9), 673-675.
17. Leung, K.C.; Johannsson, G.; Leong, G.M.; Ho, K.K. Estrogen regulation of growth hormone action. Endocr. Rev., 2004, 25(5), 693-721.
18. Siiteri, P.K. Adipose tissue as a source of hormones. Am. J. Clin. Nutr., 1987, 45(1 Suppl), 277-282.
19. Zhang, Y.; Proenca, R.; Maffei, M.; Barone, M.; Leopold, L.; Friedman, J.M. Positional cloning of the mouse obese gene and its human homologue. Nature, 1994, 372(6505), 425-432.
20. Cai, C.; Shi, F.D.; Matarese, G.; La Cava, A. Leptin as clinical target. Recent Pat. Inflamm. Allergy Drug Discov., 2009, 3(3), 160-166.
21. Casazza, K.; Hanks, L.J.; Alvarez, J.A. Role of various cytokines and growth factors in pubertal development. Med. Sport Sci., 2010, 55, 14-31.
22. Dyck, D.J. Adipokines as regulators of muscle metabolism and insulin sensitivity. Appl. Physiol. Nutr. Metab., 2009, 34(3), 396-402.
23. Vettor, R.; De Pergola, G.; Pagano, C.; Englaro, P.; Laudadio, E.; Giorgino, F.; Blum, W.F.; Giorgino, R.; Federspil, G. Gender differences in serum leptin in obese people: relationships with testosterone, body fat distribution and insulin sensitivity. Eur. J. Clin. Invest., 1997, 27(12), 1016-1024.
24. Kershaw, E.E.; Flier, J.S. Adipose tissue as an endocrine organ. J Clin Endocrinol. Metab., 2004, 89(6), 2548-2556.
25. Loskutoff, D., J., Samad, F. The adipocyte and hemostatic balance in obesity: studies of PAI-1. Arterioscler. Thromb. Vasc. Biol., 1998, 18(1), 1-6.
26. Dos Santos, E.G.; Dieudonne, M.N.; Pecquery, R.; Le Moal, V.; Giudicelli, Y.; Lacasa, D. Rapid nongenomic E2 effects on p42/p44 MAPK, activator protein-1, and cAMP response element binding protein in rat white adipocytes. Endocrinology, 2002, 143(3), 930-940.
27. Dieudonné, M.N.; Leneveu, M.C.; Giudicelli, Y.; Pecquery, R. Evidence for functional estrogen receptors alpha and beta in human adipose cells: regional specificities and regulation by estrogens. Am. J. Physiol. Cell Physiol., 2004, 286(3), C655-C661.
28. Orimo, A.; Inoue, S.; Ikegami, A.; Hosoi, T.; Akishita, M.; Ouchi, Y.; Muramatsu, M.; Orimo, H. Vascular smooth muscle cells as target for estrogen. Biochem. Biophys. Res. Commun., 1993, 195(2), 730-736.
29. Gulshan, S.; McCruden, A.B.; Stimson, W.H. Oestrogen receptors in macrophages. Scand. J. Immunol., 1990, 31(6), 691-697.
30. Cooke, P.S.; Naaz, A. Role of estrogens in adipocyte development and function. Exp. Biol. Med. (Maywood), 2004, 229(11), 1127-1135.
31. Alevizaki, M.; Saltiki, K.; Cimponeriu, A.; Kanakakis, I.; Xita, N.; Alevizaki C.C.; Georgiou, I.; Sarika, H.L. Severity of cardiovascular disease in postmenopausal women: associations with common estrogen receptor alpha polymorphic variants. Eur. J. Endocrinol., 2007, 156(4), 489-496.
32. Lo, J.C.; Zhao, X.; Scuteri, A.; Brockwell, S.; Sowers, MR. The association of genetic polymorphisms in sex hormone biosynthesis and action with insulin sensitivity and diabetes mellitus in women at midlife. Am. J. Med., 2006, 119(9 Suppl 1), S69-78.
33. Flegal, K.M.; Carroll, M.D.; Ogden, C.L.; Johnson, C.L. Prevalence and trends in obesity among US adults, 1999-2000. JAMA, 2002, 288(14), 1723-1727.
34. Sowers, M.; Zheng, H.; Tomey, K.; Karvonen-Gutierrez, C.; Jannausch, M.; Li, X.; Yosef, M.; Symons, J. Changes in body composition in women over six years at midlife: ovarian and chronological aging. J. Clin. Endocrinol. Metab., 2007, 92(3), 895-901.
35. Iwao, S.; Iwao, N.; Muller, D.C.; Elahi, D.; Shimokata, H.; Andres, R. Effect of ageingon the relationship between multiple risk factors and waist circumference. J. Am. Geriatr. Soc., 2000, 48(7), 788-794.
36. Boynton, A.; Neuhouser, M.L.; Sorensen, B.; McTiernan, A.; Ulrich, C.M. Predictors of diet quality among overweight and obese postmenopausal women. J. Am. Diet Assoc., 2008, 108(1), 125-130.
37. Iwao, S.; Iwao, N.; Muller, D.C.; Elahi, D.; Shimokata, H.; Andres, R. Does waist circumference add to the predictive power of the body mass index for coronary risk? Obes. Res., 2001, 9(11), 685-695.
38. Iwao, N.; Iwao, S.; Muller, D.C.; Elahi, D.; Shimokata, H.; Andres, R. A test of recently proposed BMI standards with respect to old age. Aging (Milano), 2000, 12(6), 461-469.
39. Kannel, W.B. The Framingham Study: historical insight on the impact of cardiovascular risk factors in men versus women. J. Gend. Specif. Med., 2002, 5(2), 27-37.
40. Mayes, J.S.; Watson, G.H. Direct effects of sex steroid hormones on adipose tissues and obesity. Obes. Rev., 2004, 5(4), 197-216.
41. D'Eon, T.M.; Souza, S.C.; Aronovitz, M.; Obin, M.S.; Fried, S.K; Greenberg, A.S. Estrogen regulation of adiposity and fuel partitioning. Evidence of genomic and non-genomic regulation of lipogenic and oxidative pathways. J. Biol. Chem., 2005, 280(43), 35983-35991.
42. Straub, R.H.; Hense, H.W.; Andus, T.; Scholmerich, J.; Riegger, G.A.; Schunkert, H. Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population-based study. J. Clin. Endocrinol. Metab., 2000, 85(3), 1340-1344.
43. Yamauchi, T.; Kamon, J.; Waki, H.; Terauchi, Y.; Kubota, N.; Hara, K, Mori, Y.; Ide, T.; Murakami, K.; Tsuboyama-Kasaoka, N.; Ezaki, O.; Akanuma, Y.; Gavrilova, O.; Vinson, C.; Reitman, M.l.; Kagechika, H.; Shudo, K.; Yoda, M.; Nakano, Y.; Tobe, K.; Nagai, R.; Kimura, S.; Tomita, M.; Froguel, P.; Kadowaki, T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med., 2001, 7, 941-946.
44. Weigert, J.; Neumeier, M.; Wanninger, J.; Wurm, S.; Kopp, A.; Schober, F.; Filarsky, M.; Schäffler, A.; Zeitoun, M.; Aslanidis, C.; Buechler, C. Reduced response to adiponectin and lower abundance of adiponectin receptor proteins in type 2 diabetic monocytes. FEBS Lett., 2008, 582(12), 1777-1782.
45. Berg, A.; H, Combs, T. P.; Du, X.; Brownlee, M.; Scherer, P.E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med., 2001, 7, 947-953.
46. Al-Daghri, N.M.; Al-Attas, O.S.; Al-Rubeaan, K.; Sallam, R. Adipocytokine profile of type 2 diabetics in metabolic syndrome as defined by various criteria. Diabetes Metab. Res. Rev., 2008, 24(1), 52-58.
47. Teijeira-Fernandez, E.; Eiras, S.; Grigorian-Shamagian, L.; Fernandez, A.; Adrio, B.; Gonzalez-Juanatey, J.R. Epicardial adipose tissue expression of adiponectin is lower in patients with hypertension. J. Hum. Hypertens., 2008, 22(12), 856-863.
48. Liang, K.W.; Sheu, W.H.; Lee, W.L.; Liu, T.J.; Ting, C.T.; Hsieh, Y.C.; Wang, K.Y.; Chen, Y.T.; Lee, W.J. Decreased circulating protective adiponectin level is associated with angiographic coronary disease progression in patients with angina pectoris. Int. J. Cardiol., 2008, 129(1), 76-80.
49. Galler, A.; Gelbrich, G.; Kratzsch, J.; Noack, N.; Kapellen, T.; Kiess, W. Elevated serum levels of adiponectin in children, adolescents and young adults with type 1 diabetes and the impact of age, gender, body mass index and metabolic control: a longitudinal study. Eur. J. Endocrinol., 2007, 157(4), 481-489.
50. Mercuro, G.; Zoncu, S.; Dragoni, F. Gender differences in cardiovascular risk factors. Ital. Heart J., 2003, 4(6), 363-366.
51. Di Croce, L.; Vicent, G.P.; Pecci, A.; Bruscalupi, G.; Trentalance, A.; Beato, M. The promoter of the rat 3-hydroxy-3-methylglutaryl coenzyme A reductase gene contains a tissue-specific estrogenresponsive region. Mol. Endocrinol., 1999, 13(8), 1225-1236.
52. Turley, S.D.; Schwarz, M.; Spady, D.K.; Dietschy, J.M. Genderrelated differences in bile acid and sterol metabolism in outbred CD-1 mice fed low- and high-cholesterol diets. Hepatology, 1998, 28(4), 1088-1094.
53. Gray, C.A.; Bartol, F.F.; Tarleton, B.J.; Wiley, A.A.; Johnson, G.A.; Bazer, F.W.; Spencer, T.E. Developmental biology of uterine glands. Biol. Reprod., 2001, 65(5), 1311-1323.
54. Shin, Y.; Vaziri, N.D.; Willekes, N.; Kim, C.H.; Joles, J.A. Effects of gender on hepatic HMG-CoA reductase, cholesterol 7alphahydroxylase, and LDL receptor in hereditary analbuminemia. Am. J. Physiol. Endocrinol. Metab., 2005, 289(6), E993-E998.
55. Angelin, B.; Olivecrona, H.; Reihnér, E.; Rudling, M.; Ståhlberg, D.; Eriksson, M.; Ewerth, S.; Henriksson, P.; Einarsson, K. Hepatic cholesterol metabolism in estrogen-treated men. Gastroenterology, 1992, 103(5), 1657-1663.
56. Chen, H.J.; Shapiro, D.J. Nucleotide sequence and estrogen induction of Xenopus laevis 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J. Biol. Chem., 1990, 265(8), 4622-4629.
57. Gilham, D.; Lehner, R. The physiological role of triacylglycerol hydrolase in lipid metabolism. Rev. Endocr. Metab. Disord., 2004, 5(4), 303-309.
58. Ma. P.T.; Yamamoto, T.; Goldstein, J.L.; Brown, M.S. Increased mRNA for low density lipoprotein receptor in livers of rabbits treated with 17 alpha-ethinyl estradiol. Proc. Natl. Acad. Sci. USA, 1986, 83(3), 792-796.
59. Mittendorfer, B.; Fields, D.A.; Klein, S. Excess body fat in men decreases plasma fatty acid availability and oxidation during endurance exercise. Am. J. Physiol. Endocrinol. Metab., 2004, 286(3), E354-E362.
60. Hussain, M.M.; Maxfield, F.R.; Más-Oliva, J.; Tabas, I.; Ji, ZS.; Innerarity, T.L.; Mahley, RW. Clearance of chylomicron remnants by the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. J. Biol. Chem., 1991, 266(21), 13936-13940.
61. Kolovou, G.D.; Anagnostopoulou, K.K.; Pilatis, N.D.; Giannopoulou, M.; Hoursalas, I.S.; Pavlidis, A.N.; Adamopoulou, E.; Valaora, A.I.; Mikhailidis, D.P.; Cokkinos, D.V. The influence of natural menopause on postprandial lipemia in heterozygotes for familial hypercholesterolemia. J. Womens Health (Larchmt)., 2004, 13(10), 1119-1126.
62. Windler, E.E.; Kovanen, P.T.; Chao, Y.S.; Brown, M.S.; Havel, R.J.; Goldstein, J.L. The estradiol-stimulated lipoprotein receptor of rat liver. A binding site that membrane mediates the uptake of rat lipoproteins containing apoproteins B and E. J. Biol. Chem., 1980, 255(21), 10464-10471.
63. Stangl, H.; Graf, G.A.; Yu, L.; Cao, G.; Wyne, K. Effect of estrogen on scavenger receptor BI expression in the rat. J. Endocrinol., 2002, 175(3), 663-672.
64. Olofsson, S.O.; Wiklund, O.; Boren, J. Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease. Vasc. Health Risk Manag., 2007, 3(4), 491-502.
65. Hofmann, AF. The enterohepatic circulation of bile acids in mammals: form and functions. Front. Biosci., 2009, 14, 2584-2598.
66. Daniels, T.F.; Killinger, K.M.; Michal, J.J.; Wright, R.W. Jr.; Jiang, Z. Lipoproteins, cholesterol homeostasis and cardiac health. Int. J. Biol. Sci., 2009, 5(5), 474-488.
67. Makishima, M.; Okamoto, A.Y.; Repa, J.J.; Tu, H.; Learned, R.M.; Luk, A.; Hull, M.V.; Lustig, K.D.; Mangelsdorf, D.J.; Shan, B. Identification of a nuclear receptor for bile acids. Science, 1999, 284(5418), 1362-1365.
68. Colvin, P.L. Jr.; Wagner, J.D.; Adams, M.R.; Sorci-Thomas, M.G. Sex steroids increase cholesterol 7alpha-hydroxylase mRNA in nonhuman primates. Metabolism, 1998, 47(4), 391-395.
69. Xu, G.; Salen, G.; Shefer, S.; Ness, G.C.; Nguyen, L.B.; Tint, G.S.; Parker, T.S.; Roberts, J.; Batta, A.K.; Chen, T.S.; Zhao, Z.; Kong, X. Increasing hepatic cholesterol 7alpha-hydroxylase reduces plasma cholesterol concentrations in normocholesterolemic and hypercholesterolemic rabbits. Hepatology, 1996, 24(4), 882-887.
70. Rifici, V.A.; Khachadurian, A.K. The inhibition of low-density lipoprotein oxidation by 17-beta estradiol. Metabolism, 1992, 41(10), 1110-1114.
71. Mudali, S.; Dobs, A.S.; Ding, J.; Cauley, J.A.; Szklo, M.; Golden, S.H. Endogenous postmenopausal hormones and serum lipids: the atherosclerosis risk in communities study. J. Clin. Endocrinol. Metab., 2005, 90(2), 1202-1209.
72. Golden, S.H.; Maguire, A.; Ding, J.; Crouse, J.R.; Cauley, J.A.; Zacur, H.; Szklo, M. Endogenous postmenopausal hormones and carotid atherosclerosis: a case-control study of the atherosclerosis risk in communities cohort. Am. J. Epidemiol., 2002, 155(5), 437-445.
73. Shearman, A.M.; Demissie, S.; Cupples, L.A.; Peter, I.; Schmid, C.H.; Ordovas, J.M.; Mendelsohn, M.E.; Housman, D.E. Tobacco smoking, estrogen receptor alpha gene variation and small low density lipoprotein level. Hum. Mol. Genet., 2005, 14(16), 2405-2413.
74. Derby, C.A.; Crawford, S.L.; Pasternak, R.C.; Sowers, M.; Sternfeld, B.; Matthews, K.A. Lipid changes during the menopause transition in relation to age and weight: the Study of Women's Health Across the Nation. Am. J. Epidemiol. 2009, 169(11), 1352-61.
75. Graff-Iversen S, Thelle DS, Hammar N. Serum lipids, blood pressure and body weight around the age of the menopause. Eur. J. Cardiovasc. Prev. Rehabil., 2008, 15(1), 83-8.
76. Woodard, G.A.; Brooks, M.M.; Barinas-Mitchell, E.; Mackey, R.H.; Matthews, K.A.; Sutton-Tyrrell, K. Lipids, menopause, and early atherosclerosis in Study of Women's Health Across the Nation Heart women. Menopause, 2011, 18(4), 376-384.
77. Reaven, G.M. Banting Lecture 1988. Role of insulin resistance in human disease. Nutrition, 1997, 13(1), 65, discussion 4, 6.
78. Fritsch, F.E. Prof. Johan Harald Kylin. Nature, 1950, 165(4198), 588.
79. Kolovou, G.D.; Anagnostopoulou, K.K.; Salpea, K.D.; Mikhailidis, D.P. The prevalence of metabolic syndrome in various populations. Am. J. Med. Sci., 2007, 333(6), 362-371.
80. Kolovou, G.D.; Anagnostopoulou, K.K.; Pavlidis, A.N.; Salpea, K.D.; Iraklianou, S.A.; Hoursalas, I.S.; Mikhailidis, D.P.; Cokkinos, D,V. Metabolic syndrome and gender differences in postprandial lipaemia. Eur. J. Cardiovasc. Prev. Rehabil., 2006, 13(4), 661-664.
81. Daskalopoulou, S.S.; Athyros, V.G.; Kolovou G.D.; Anagnostopoulou, K.K.; Mikhailidis, D.P. Definitions of metabolic syndrome: Where are we now? Curr. Vasc. Pharmacol., 2006, 4(3), 185-197.
82. Kolovou, G.D.; Anagnostopoulou, K.K.; Pavlidis, A.N.; Salpea, K.D.; Iraklianou, S.A.; Tsarpalis, K.; Damaskos, D.S.; Manolis, A.; Cokkinos, D.V. Postprandial lipemia in men with metabolic syndrome, hypertensives and healthy subjects. Lipids Health Dis., 2005, 4, 21.
83. Kolovou, G.D.; Anagnostopoulou, K.K.; Cokkinos, D.V. Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgrad. Med. J., 2005, 81(956), 358-366.
84. Musatov, S.; Chen, W.; Pfaff, D.W.; Mobbs, C.V.; Yang, X.J.; Clegg, D.J.; Kaplitt, M.G.; Ogawa, S. Silencing of estrogen receptor alpha in the ventromedial nucleus of hypothalamus leads to metabolic syndrome. Proc. Natl. Acad. Sci. U S A, 2007, 104(7), 2501-2506.
85. Tzou, W.S.; Douglas, P.S.; Srinivasan, S.R.; Bond, M.G.; Tang, R.; Chen, W, Berenson GS, Stein JH. Increased subclinical atherosclerosis in young adults with metabolic syndrome: the Bogalusa Heart Study. J. Am. Coll. Cardiol., 2005, 46(3), 457-463.
86. Turhan, H.; Yasar, A.S.; Basar, N.; Bicer, A.; Erbay, A.R.; Yetkin, E. High prevalence of metabolic syndrome among young women with premature coronary artery disease. Coron. Artery Dis., 2005, 16(1), 37-40.
87. Egred, M.; Viswanathan, G.; Davis, G.K. Myocardial infarction in young adults. Postgrad. Med. J., 2005, 81(962), 741-745.
88. Yasar, A.S.; Turhan, H.; Basar, N.; Metin, F.; Erbay, A.R.; Ilkay, E.; Sabah, I. Comparison of major coronary risk factors in female and male patients with premature coronary artery disease. Acta. Cardiol., 2008, 63(1), 19-25.
89. Towfighi, A.; Zheng, L.; Ovbiagele, B. Sex-specific trends in midlife coronary heart disease risk and prevalence. Arch. Intern. Med., 2009, 169, 1762-1766.
90. Kolovou, G.; Giannakopoulou, V.; Vasiliadis, Y.; Bilianou, H. Effects of estrogens on atherogenesis. Curr. Vasc. Pharmacol., 2011, 9(2), 244-257.
91. Gulati, M.; Shaw, L.; Merz, N. Myocardial ischemia in women: lessons from the NHLBI WISE study. Clin. Cardiol., 2012, 35, 141-148.
92. Kochaneck, K.D.; Xu, J.; Murphy, S.L.; Minino, A.M.; Kung, H-C. Deaths: Preliminary Data for 2009. National Vital. Statistics Reports, 2011, 59, 1-51.
93. Roger, V.L.; Go, A.S.; Lloyd-Jones, D.M.; Benjamin, E.J.; Berry, J.D.; Borden, W.B.; Bravata, D.M.; Dai, S.; Ford, E.S.; Fox, C.S.; Fullerton, H.J.; Gillespie, C.; Hailpern, S.M.; Heit, J.A.; Howard, V.J.; Kissela, B.M.; Kittner, S.J.; Lackland, D.T.; Lichtman, J.H.; Lisabeth, L.D.; Makuc, D.M.; Marcus, G.M.; Marelli, A.; Matchar, D.B.; Moy, C.S.; Mozaffarian, D.; Mussolino, M.E.; Nichol, G.; Paynter, N.P.; Soliman, E.Z.; Sorlie, P.D.; Sotoodehnia, N.; Turan, T.N.; Virani, S.S.; Wong, N.D.; Woo, D.; Turner, M.B; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation, 2011, 123, e18-e209.
94. Ni, H.; Coady, S.; Rosamond, W.; Folsom, A.R.; Chambless, L.; Russell, S.D.; Sorlie, P.D. Trends from 1987 to 2004 in sudden death due to coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Am. Heart J., 2009, 157, 46-52.
95. Lakka, H.M.; Laaksonen, D.E.; Lakka, T.A.; Niskanen, L.K.; Kumpusalo, E.; Tuomilehto, J.; Salonen, J.T. The metabolic syndrome and total and cardiovascular disease mortality in middleaged men. JAMA, 2002, 288, 2709-2716.
96. Ford, E.S.; Giles, W.H.; Dietz, W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA, 2002, 287, 356-359.
97. Ramos, R.G.; Olden, K. The prevalence of metabolic syndrome among US women of childbearing age. Am. J. Public Health, 2008, 98, 1122-1127.
98. Gami, A.S.; Witt, B.J.; Howard, D.E.; Erwin, P.J.; Gami, L.A.; Somers, V.K.; Montori, V.M. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J. Am. Coll. Cardiol., 2007, 49, 403-414.
99. Mokdad, A.H.; Ford, E.S.; Bowman, B.A.; Dietz, W.H.; Vinicor, F.; Bales, V.S.; Marks, J.S. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA, 2003, 289, 76-79.
100. Lloyd-Jones, D.M.; Leip, E.P.; Larson, M.G.; D'Agostino, R.B.; Beiser, A.; Wilson, P.W.; Wolf, P.A.; Levy, D. Prediction of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years of Age. Circulation, 2006, 113, 791-798.
101. Daviglus, M.L.; Stamler, J.; Pirzada, A.; Yan, L.L.; Garside, D.B.; Liu, K.; Wang, R.; Dyer, A.R.; Lloyd-Jones, D.M.; Greenland, P. Favorable cardiovascular risk profile in young women and longterm risk of cardiovascular and all-cause mortality. JAMA, 2004, 292, 1588-1592.
102. Barton, M. Cholesterol and atherosclerosis: modulation by oestrogen. Curr. Opin. Lipidol., 2013, 24(3), 214-220.
103. Wild, R.A.; Wu, C.; Curb, J.D.; Martin, L.W.; Phillips, L.; Stefanick, M.; Trevisan, M.; Manson, J.E. Coronary heart disease events in the Women's Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women's Health Initiative randomized clinical trials. Menopause, 2013, 20(3), 254-260.
104. Martín-Millán, M.; Castañeda, S. Estrogens, osteoarthritis and inflammation. Joint Bone Spine, 2013, pii: S1297-319X(12), 00311-00319.
105. de Padua Mansur, A.; Silva, T.C.; Takada, J.Y.; Avakian, S.D.; Strunz, C.M.; Machado César, L.A.; Mendes Aldrighi, J.; Ramires, J.A. Long-term prospective study of the influence of estrone levels on events in postmenopausal women with or at high risk for coronary artery disease. Scientific World J., 2012, 2012, 363595, doi: 10.1100/2012/363595, Epub 2012 Jun 4.
106. Schnatz, PF. Hormonal therapy: does it increase or decrease cardiovascular risk? Obstet. Gynecol. Surv., 2006, 61(10), 673-681.
107. Fait, T.; Vrablik, M. Coronary heart disease and hormone replacement therapy - from primary and secondary prevention to the window of opportunity. Neuro. Endocrinol. Lett., 2012, 33 Suppl 2, 17-21.
108. Manson, J.E.; Chlebowski, R.T.; Stefanick, M.L.; Aragaki, A.K.; Rossouw, J.E.; Prentice, R.L.; Anderson, G.; Howard, B.V.; Thomson, C.A.; LaCroix, A.Z.; Wactawski-Wende, J.; Jackson, R.D.; Limacher, M.; Margolis, K.L.; Wassertheil-Smoller, S.; Beresford, S.A.; Cauley, J.A.; Eaton, CB.; Gass, M.; Hsia, J.; Johnson, K.C.; Kooperberg, C.; Kuller L.H.; Lewis, C.E.; Liu, S.; Martin, L.W.; Ockene, J.K.; O'Sullivan, M.J.; Powell, L.H.; Simon, M.S.; Van Horn, L.; Vitolins, M.Z.; Wallace, R.B. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA, 2013, 310(13), 1353-1368.
109. Mosca, L.; Benjamin, E.J.; Berra, K.; Bezanson, J.L.; Dolor, R.J.; Lloyd-Jones, D.M.; Newby, L.K.; Piña, I.L.; Roger, V.L.; Shaw, L.J.; Zhao, D.; Beckie, T.M.; Bushnell, C.; D'Armiento, J.; Kris-Etherton, P.M.; Fang, J.; Ganiats, T.G.; Gomes, A.S.; Gracia, C.R.; Haan, C.K.; Jackson, E.A.; Judelson, D.R.; Kelepouris, E.; Lavie, C.J.; Moore, A.; Nussmeier, N.A.; Ofili, E.; Oparil, S.; Ouyang, P.; Pinn, V.W.; Sherif, K.; Smith, S.C. Jr, Sopko, G.; Chandra-Strobos, N.; Urbina, E.M.; Vaccarino, V.; Wenger, N.K. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the american heart association. Circulation, 2011, 123(11), 1243-1262.
110. Lindquist, R.; Witt, D.R.; Boucher, J.L. Preventing cardiovascular disease in women: how can we do better? Curr. Opin. Cardiol., 2012, 27(5), 542-549.
111. Britton, K.A.; Massaro, J.M.; Murabito, J.M.; Kreger, B.E.; Hoffmann, U.; Fox, C.S. Body Fat Distribution, Incident Cardiovascular Disease, Cancer, and All-cause Mortality. J. Am. Coll. Cardiol., 2013, 1, S0735-1097(13), 02554-0.
112. Snijder, M.B.; van Dam, R.M.; Visser, M.; Seidell, J.C. What aspects of body fat are particularly hazardous and how do we measure them? Int. J. Epidemiol., 2006, 35, 83-92.
113. Wake, R.; Yoshiyama, M. Gender differences in ischemic heart disease. Recent Pat. Cardiovasc. Drug Discov., 2009, 4, 234-240.
114. Izawa, K.P.; Oka, K.; Watanabe, S.; Yokoyama, H.; Hiraki, K.; Morio, Y.; Kasahara, Y.; Omiya, K. Gender-related differences in clinical characteristics and physiological and psychosocial outcomes of Japanese patients at entry into phase II cardiac rehabilitation. J. Rehabil. Med., 2008, 40, 225-230.
115. Tabassum, F.; Batty, G.D. Are current UK National Institute for Health and Clinical Excellence (NICE) obesity risk guidelines useful? Cross-sectional associations with cardiovascular disease risk factors in a large, representative english population. PLoS One, 2013, 2, 8(7), e67764.
116. Félix-Redondo, F.J.; Grau, M.; Baena-Díez, J.M.; Dégano, I.R.; de León, A.C.; Guembe, M.J.; Alzamora, M.T.; Vega-Alonso, T.; Robles, N.R.; Ortiz, H.; Rigo, F.; Mayoral-Sanchez, E.; Tormo, M.J.; Segura-Fragoso, A.; Fernández-Bergés, D. Prevalence of obesity and associated cardiovascular risk: the DARIOS study. BMC Public Health, 2013, 5:13(1), 542.
117. Wilson, P.W.; D'Agostino, R.B.; Sullivan, L.; Parise, H.; Kannel, W.B. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch, Intern, Med., 2002, 13(16), 1867-1872.
118. Sclavo, M. Cardiovascular risk factors and prevention in women: similarities and differences. Ital. Heart. J. Suppl., 2002, 2(2), 125-141.
119. Van Dis, I.; Kromhout, D.; Geleijnse, J.M.; Boer, J.M.; Verschuren, W.M. Body mass index and waist circumference predict both 10-year nonfatal and fatal cardiovascular disease risk: study conducted in 20,000 Dutch men and women aged 20-65 years. Eur. J. Cardiovasc. Prev. Rehabil., 2009, 16(6), 729-734.
120. US Burden of Disease Collaborators, The state of US health, 1990-2010: burden of diseases, injuries, and risk factors, [published online July 10, 2013] JAMA.
121. Misra, A..; Sharma, R.; Gulati, S.; Joshi, S.R.; Sharma, V.; Ghafoorunissa Ibrahim, A.; Joshi, S.; Laxmaiah, A.; Kurpad, A.; Raj, R.K.; Mohan, V.; Chandalia, H.; Krishnaswamy, K.; Boindala, S.; Gopalan, S.; Bhattiprolu, S.K.; Modi, S.; Vikram, N.K.; Makkar, B.M.; Mathur, M.; Dey, S.; Vasudevan, S.; Gupta, S.P.; Puri, S.; Joshi, P.; Khanna, K.; Mathur, P.; Krishnaswamy, S.; Madan, J.; Karmarkar, M.; Seth, V.; Passi, S.J.; Chadha, D.; Bhardwaj, S. National Dietary Guidelines Consensus Group. Consensus dietary guidelines for healthy living and prevention of obesity, the metabolic syndrome, diabetes, and related disorders in Asian Indians. Diabetes Technol. Ther., 2011, 13, 683-694.
122. Misra, A.; Nigam, P.; Hills, A.P.; Chadha, D.S.; Sharma, V.; Deepak, K.K.; Vikram, N.K.; Joshi, S.; Chauhan, A.; Khanna, K.; Sharma, R.; Mittal, K.; Passi, S.J.; Seth, V.; Puri, S.; Devi, R.; Dubey, A.P.; Gupta, S. Physical Activity Consensus Group. Consensus physical activity guidelines for Asian Indians. Diabetes Technol. Ther., 2012, 14, 83-98.
123. Howell, A.; Evans, GD. Hormone replacement therapy and breast cancer. Recent Results Cancer Res., 2011, 188, 115-124.
124. Santen, R.J.; Allred, D.C.; Ardoin, S.P.; Archer, D.F.; Boyd, N.; Braunstein, G.D.; Burger, H.G.; Colditz, G.A.; Davis, S.R.; Gambacciani, M.; Gower, B.A.; Henderson, V.W.; Jarjour, W.N.; Karas, R.H.; Kleerekoper, M.; Lobo, R.A.; Manson, J.E.; Marsden, J.; Martin, K.A.; Martin, L.; Pinkerton, J.V.; Rubinow, D.R.; Teede, H.; Thiboutot, D.M.; Utian, W.H. Endocrine Society. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J. Clin. Endocrinol. Metab., 2010, 95(7 Suppl 1), s1-s66.
125. Panay, N. Estrogen dose: the cardiovascular impact. Climacteric, 2009, 12 Suppl 1, 91-95.
126. Billeci, A.M.; Paciaroni, M.; Caso, V.; Agnelli, G. Hormone replacement therapy and stroke. Curr. Vasc. Pharmacol., 2008, 6(2), 112-123.
127. Greiser, C.M.; Greiser, E.M.; Doren, M. Menopausal hormone therapy and risk of lung cancer-Systematic review and metaanalysis. Maturitas, 2010, 65(3), 198-204.
128. Dubey, R.K.; Imthurn, B.; Zacharia, L.C.; Jackson, E.K. Hormone replacement therapy and cardiovascular disease: what went wrong and where do we go from here? Hypertension, 2004, 44(6), 789-795.
129. Hulley, S.; Grady, D.; Bush, T.; Furberg, C.; Herrington, D.; Riggs, B.; Vittinghoff, E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA, 1998, 280(7), 605-613.
130. Rossouw, J.E.; Anderson, G.L.; Prentice, R.L.; LaCroix, A.Z.; Kooperberg, C.; Stefanick, M.L.; Jackson, R.D.; Beresford, S.A.; Howard, B.V.; Johnson, K.C.; Kotchen, J.M.; Ockene, J. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA, 2002, 288(3), 321-333.
131. Rosano GM, Vitale C, Fini M. Cardiovascular aspects of menopausal hormone replacement therapy. Climacteric, 2009, 12 Suppl 1, 41-46.
132. Taylor H.S.; Manson, J.E. Update in hormone therapy use in menopause. J. Clin. Endocrinol. Metab., 2011, 96(2), 255-264.
133. Salpeter, S.R.; Cheng, J.; Thabane, L.; Buckley, N.S.; Salpeter, E.E. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. Am. J, Med., 2009, 122(11), 1016-1022 e1.
134. Shifren, J.L.; Schiff, I. Role of hormone therapy in the management of menopause. Obstet. Gynecol., 2010, 115(4), 839-855.
135. Pearce, C.L.; Chung, K.; Pike, M.C.; Wu, A.H. Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. Cancer, 2009, 115(3), 531-539.
136. rd; Chung, R.J.; Michelson, A.D.; Neufeld, E.J.; Gordon, C.M.; Laufer, M.R.; Emans, S.J. Hormonal contraception and thrombotic risk: a multidisciplinary approach. Pediatrics, 2011, 127(2), 347-357.
137. Fournier, A. Should transdermal rather than oral estrogens be used in menopausal hormone therapy? A review. Menopause Int., 2010, 16(1), 23-32.
138. Lambrinoudaki, I.; Brincat, M.; Erel, C.T.; Gambacciani, M.; Moen, M.H.; Schenck-Gustafsson, K.; Tremollieres, F.; Vujovic, S.; Rees, M.; Rozenberg, S. EMAS position statement: managing obese postmenopausal women. Maturitas, 2010, 66(3), 323-326.
139. Schenck-Gustafsson, K.; Brincat, M.; Erel, C.T.; Gambacciani, M.; Lambrinoudaki, I.; Moen, M.H.; Tremollieres, F.; Vujovic, S.; Rozenberg, S.; Rees, M; EMAS. EMAS position statement: Managing the menopause in the context of coronary heart disease. Maturitas, 2011, 68(1), 94-97.
140. North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause, 2010, 17(2), 242-255.
141. Ostberg, J.E.; Damjanovic, T.; Dimkovic, N.; Byrne, D.; Mikhailidis, D.P.; Prelevic, G.M. Effect of tibolone on markers of cardiovascular disease risk in postmenopausal women undergoing hemodialysis: a pilot study. Fertil. Steril., 2004, 81(6), 1624-1631.
142. Stojanovic, N.D.; Kwong, P.; Byrne, D.J.; Arnold, A.; Jagroop, I.A.; Nair, D.; Press, M.; Hurel, S.; Mikhailidis, D.P.; Prelevic, G.M. The effects of transdermal estradiol alone or with cyclical dydrogesterone on markers of cardiovascular disease risk in postmenopausal women with type 2 diabetes: a pilot study. Angiology, 2003, 54(4), 391-399.
143. Prelevic, G.M.; Kwong, P.; Byrne, D.J.; Jagroop, I.A.; Ginsburg, J.; Mikhailidis, D.P. A cross-sectional study of the effects of hormon replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women. Fertil. Steril., 2002, 77(5), 945-951.
144. U.S. Preventive Services Task Force. Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the U.S. Preventive Services Task Force. Ann. Intern. Med., 2005, 142(10), 855-860.
145. Moyer, V.A.; U.S. Preventive Services Task Force. Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med., 2013, 158(1), 47-54.